Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
The wave of layoffs, which began last year with the declines in COVID-19 testing sales, has gathered momentum in 2023.
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
A recent court case sheds some light on if denying employment can count as illegal remuneration under the Anti-Kickback Statute.
Two companies settle kickback and FCA-related claims, a qui tam case is tossed, and a lab tech loses a workplace harassment case.
In an analysis of enforcement actions from the end of 2022 to early spring 2023, cases involving urine drug testing were the most prevalent.
Auditing in medical laboratories is critical for reviewing processes to identify erroneous outcomes, as well as areas for improvement.
This Lab Institute session will share how lab leaders can gain an advantage in today’s tight pathology job market.
Though there are currently no clinical guidelines for their use, PRSs are being widely used in health care.